May 22 2013 – Promedior Presents Encouraging Results from Clinical Study of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis

LEXINGTON, Mass., May 22, 2013 —Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, unveiled data from a clinical study of PRM-151 in an oral presentation at the 2013 American Thoracic Society (ATS) International Conference in Philadelphia. The clinical data from a randomized, double-blind, placebo controlled Phase 1b multiple ascending dose study showed that PRM-151 was generally safe and well tolerated in patients with idiopathic pulmonary fibrosis (IPF). In addition, the study showed encouraging results in exploratory efficacy endpoints.

“We are excited to present data from this clinical study, which underscore the safety and potential of PRM-151 as a novel therapeutic to treat IPF, a serious and life threatening orphan fibrotic disease,” said Beth Trehu, MD, FACP, Chief Medical Officer. “The safety profile and intriguing efficacy signals seen in this Phase 1b multiple dose trial of PRM-151 in patients with IPF support advancement of this clinical program to Phase 2. We are also initiating clinical development of PRM-151 in myelofibrosis, another serious and life threatening orphan fibrotic disease.”

Read the entire article at:

http://www.promedior.com/news/releases/2013%200522%20Promedior%20PRM-151%20IBS%20Ph1b%20Results.html

For more information about Idiopathic Pulmonary Fibrosis please visit: www.ipftoday.com

 

This entry was posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized and tagged , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>